GB201815045D0 - Bispecific antibody targeting IL-1R1 and NLPR3 - Google Patents

Bispecific antibody targeting IL-1R1 and NLPR3

Info

Publication number
GB201815045D0
GB201815045D0 GBGB1815045.8A GB201815045A GB201815045D0 GB 201815045 D0 GB201815045 D0 GB 201815045D0 GB 201815045 A GB201815045 A GB 201815045A GB 201815045 D0 GB201815045 D0 GB 201815045D0
Authority
GB
United Kingdom
Prior art keywords
nlpr3
bispecific antibody
antibody targeting
targeting
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1815045.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Priority to GBGB1815045.8A priority Critical patent/GB201815045D0/en
Publication of GB201815045D0 publication Critical patent/GB201815045D0/en
Priority to US17/275,995 priority patent/US12227579B2/en
Priority to PCT/EP2019/074744 priority patent/WO2020053446A1/en
Priority to EP19769487.0A priority patent/EP3849662A1/en
Priority to PCT/EP2019/074745 priority patent/WO2020053447A1/en
Priority to EP19769486.2A priority patent/EP3849661A1/en
Priority to CN201980074106.7A priority patent/CN112996564A/zh
Priority to US17/275,986 priority patent/US12264201B2/en
Priority to JP2021514418A priority patent/JP7645544B2/ja
Priority to AU2019338674A priority patent/AU2019338674B2/en
Priority to CN201980074059.6A priority patent/CN112996563A/zh
Priority to JP2021514423A priority patent/JP7517702B2/ja
Priority to AU2019338955A priority patent/AU2019338955B2/en
Priority to JP2024104327A priority patent/JP2024125385A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1815045.8A 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3 Ceased GB201815045D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
AU2019338955A AU2019338955B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3
CN201980074106.7A CN112996564A (zh) 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体
JP2021514418A JP7645544B2 (ja) 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
EP19769487.0A EP3849662A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3
PCT/EP2019/074745 WO2020053447A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3
EP19769486.2A EP3849661A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3
US17/275,995 US12227579B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLPR3
US17/275,986 US12264201B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074744 WO2020053446A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3
AU2019338674A AU2019338674B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3
CN201980074059.6A CN112996563A (zh) 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体
JP2021514423A JP7517702B2 (ja) 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
JP2024104327A JP2024125385A (ja) 2018-09-14 2024-06-27 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3

Publications (1)

Publication Number Publication Date
GB201815045D0 true GB201815045D0 (en) 2018-10-31

Family

ID=64013420

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1815045.8A Ceased GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3

Country Status (7)

Country Link
US (2) US12264201B2 (https=)
EP (2) EP3849662A1 (https=)
JP (3) JP7645544B2 (https=)
CN (2) CN112996564A (https=)
AU (2) AU2019338674B2 (https=)
GB (1) GB201815045D0 (https=)
WO (2) WO2020053446A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991366T3 (es) 2020-05-08 2024-12-03 Halia Therapeutics Inc Inhibidores de NEK7 cinasa
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN119074914B (zh) * 2023-06-05 2025-04-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN119080928B (zh) * 2023-06-05 2025-07-08 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061005A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2007081982A2 (en) 2006-01-10 2007-07-19 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
RU2013110844A (ru) * 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2013007763A1 (en) 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
CA2861031C (en) * 2012-02-03 2022-10-25 Carole BOURQUIN Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
AU2013231851A1 (en) 2012-03-15 2014-09-11 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
NZ760541A (en) * 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
US20160354437A1 (en) 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
WO2017079352A2 (en) * 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
JP2019507796A (ja) * 2016-03-11 2019-03-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド イカリイン及びイカリチン誘導体
US10041044B2 (en) * 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Also Published As

Publication number Publication date
WO2020053447A1 (en) 2020-03-19
AU2019338955B2 (en) 2026-03-19
US12227579B2 (en) 2025-02-18
JP7645544B2 (ja) 2025-03-14
CN112996564A (zh) 2021-06-18
US20220033507A1 (en) 2022-02-03
AU2019338674A1 (en) 2021-04-22
WO2020053446A1 (en) 2020-03-19
US12264201B2 (en) 2025-04-01
EP3849662A1 (en) 2021-07-21
JP7517702B2 (ja) 2024-07-17
JP2022500457A (ja) 2022-01-04
JP2022500455A (ja) 2022-01-04
AU2019338674B2 (en) 2026-02-05
EP3849661A1 (en) 2021-07-21
AU2019338955A1 (en) 2021-04-15
CN112996563A (zh) 2021-06-18
US20220041739A1 (en) 2022-02-10
JP2024125385A (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
HUS2500032I1 (hu) Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
IL278846A (en) Anti-CD3 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
ZA201908072B (en) Igf-1r monoclonal antibodies and uses thereof
IL279455A (en) ANTI-PD-1 antibodies and their uses
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL268051A (en) Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
ZA202004908B (en) Bispecific antibody
EP3661555C0 (en) BISPECIFIC ANTIBODIES AND THEIR USES
IL278466B1 (en) Anti-dll3 antibodies and uses thereof
IL276675A (en) Anti-PD-1 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
GB201815045D0 (en) Bispecific antibody targeting IL-1R1 and NLPR3
IL283180A (en) Anti-PD-1 antibodies and their uses
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL278862A (en) Monospecific and multispecific anti-TMEFF2 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
IL283890A (en) Anti-periostin antibodies and their uses
IL282030A (en) Antibodies to EPN1
GB201918230D0 (en) Antibodies and their uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)